Generate a tailored SOP for Dr. Tommy Andersson. Improve your application with a focused, well-structured draft.
Tommy Andersson is an expert in Experimental Pathology at Lund University, leading research focused on the role of WNT5A, a non-transforming class of WNT secreted glycoprotein, in cancer biology. His studies investigate the complex signaling pathways of WNT5A, which can act as both a tumor promoter and tumor suppressor depending on the cellular context. He has established that loss of WNT5A is linked to poor survival rates in breast cancer, while its expression enhances metastasis and reduces survival in melanoma. His research is pioneering therapeutic innovations, including the development of the hexapeptide Foxy5, an agonist of WNT5A currently in Phase 1 clinical trials for breast cancer, prostate cancer, and colon carcinoma. Andersson's laboratory aims to unravel the intricate regulation of WNT5A expression in various cancers, focusing on its impact on cancer cell migration and invasion. He aligns his work with the UN Sustainable Development Goals, contributing to global efforts to combat cancer and its related challenges.
Lund University • Lund, Sweden
Leading research on WNT5A signaling pathways in cancer.
Includes Master of Science in Politics and Society of the Contemporary Middle East and European Affairs.